Navigation Links
EpiVax-Novozymes Tregitope-Albumin Fusion Moves 'Paradigm-Shifting' Treatment for Diabetes Closer to Clinical Trials
Date:2/12/2013

PROVIDENCE, R.I., Feb. 12, 2013 /PRNewswire/ -- EpiVax, Inc. is pleased to announce a new Collaborative Research Agreement with Novozymes Biopharma. The collaboration will enable EpiVax to rapidly advance its Tregitope immune-modulating technology as a potential treatment for autoimmune diseases. When used as a buffering agent, albumin has excellent safety and pharmacokinetic profiles. Fusing Tregitopes to Novozymes' proven albumin-based half-life extension platform will create a safe and effective vehicle for the application of Tregitopes to multiple problems in the areas of autoimmunity, transplantation, and allergy.

(Logo: http://photos.prnewswire.com/prnh/20121116/NE15175LOGO )

Tregitopes, discovered by Anne De Groot and Bill Martin at EpiVax, are linear sequences of amino acids contained within the framework of monoclonal antibodies and immunoglobulin G; the original finding was published in the journal Blood in 2008. Since their discovery, EpiVax has compiled substantial evidence linking Tregitopes to the activation of natural regulatory T cells. By selectively activating these natural regulatory T cells, Tregitopes can dampen unwanted immune responses. Preliminary studies carried out by EpiVax and collaborators indicate that Tregitopes may be useful for inducing tolerance to transplants, protein drugs, and blood replacement therapies, as well as for the treatment of allergies. EpiVax believes Tregitopes may explain the effectiveness of intravenous immunoglobulin G (IVIG), widely utilized as an autoimmune treatment (a $4B annual market).

The initial disease target for Tregitope therapy with the albumin-Tregitope fusion will be Type 1 diabetes (T1D). Each year, more than 13,000 young people are diagnosed with T1D. Islet replacement t
'/>"/>

SOURCE EpiVax, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. CareFusion Launches New Take-Apart Laparoscopic Scissors
2. CareFusion Reports First Half Fiscal 2013 Results
3. CareFusion Files Fiscal 2012 Form 10-K
4. B. Braun Smart Infusion Pump Technology Advances Patient Safety and Treatment Efficiency
5. Global Spinal Nonfusion Market to Grow to $1 Billion by 2017, Despite Challenges
6. Hospira and Q Core Medical Sign International Distribution Agreement for Sapphire Infusion System
7. CareFusion Launches New Preoperative Cleansing Program For In-Home Patient Use
8. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
9. Practice Fusion Announces Free EMR for iPad in Beta
10. CareFusion Reports Preliminary First Quarter Fiscal 2013 Results
11. CareFusion To Report Preliminary Fiscal 2013 First Quarter Results On Nov. 8
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
(Date:1/14/2014)... Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a ... it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... terms of the acquisition were not disclosed. ... providing a wide range of sleep, mobility, and respiratory products ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), ... pipeline update webcast/conference call after the market closes on ... Officer, Vicente Anido, Jr., Ph.D., and Chief Financial Officer ... provide 2011 guidance, give a commercial and new product ...
... OSAKA, Japan, Dec. 21, 2010 Takeda Pharmaceutical ... its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc. ... patent litigation brought against the companies in response ... generic ACTOS® (pioglitazone HCl), ACTO plus met® ...
Cached Medicine Technology:ISTA Pharmaceuticals Announces 2011 Guidance and Pipeline Update Webcast/Conference Call on January 5, 2011 2Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 2Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 3Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 4Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 5Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 6
(Date:7/9/2014)... type of lung cancer, researchers have uncovered mutations in ... tumors. The new knowledge may expand treatments for patients ... are available or are in clinical trials. , Reporting ... Cancer Genome Atlas (TCGA), including researchers at Washington University ... and other institutions, studied tumors from 230 patients with ...
(Date:7/9/2014)... -- Researchers from The Miriam Hospital have ... (COPD) who are also depressed have difficulty sticking ... be particularly true for women, and screening and ... part of treatment. The study and its findings ... . , Chronic obstructive pulmonary disease is ...
(Date:7/9/2014)... KNOXVILLEAmphibian declines and extinctions around the world have ... chytridiomycosis, but new research from the National Institute ... another pathogen, ranavirus, may also contribute. , ... that ranavirus, which causes severe hemorrhage of internal ... populations of wood frogs if they are exposed ...
(Date:7/9/2014)... retrospective study conducted by researchers at Tufts University School ... with intellectual and developmental disabilities, the likelihood of having ... care increased. The findings, published in the July/August issue ... improve interventions designed to address the oral health of ... the dental records of 107 patients at one of ...
(Date:7/9/2014)... allergic diseases has risen dramatically in Western societies. One ... to microorganisms and have fewer infections than previous generations, ... study by researchers at Sahlgrenska Academy, University of Gothenburg, ... maturation of the immune system in relation to allergic ... of the Vstra Gtaland Region, half of them on ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3
... APS Healthcare, a leading provider of specialty healthcare solutions, ... Services to deliver a unified total population health management ... the State consolidated its service providers from three to ... population that APS has been serving for the past ...
... PROSPECT, Ill., May 5 The National Association of ... May 5, 2009, examining the flagrant lawlessness of Web ... why this ,wild west, of an electronic marketplace is ... dead and injured patients," the paper asserts. The "State ...
... May 5 Tim Wentworth, group president, employer accounts, Medco ... to address the Bank of America/Merrill Lynch 2009 Health Care ... at the Palace Hotel in New York City, will begin ... officer, is also scheduled to attend.The presentation may be heard ...
... in one Minnesota city , , TUESDAY, May 5 (HealthDay ... known, another learning disability -- the inability to write ... new study suggests. , So-called written-language disorder is a ... epidemiologist at the Mayo Clinic and lead author of ...
... with elevated albumin levels were more likely to get ... News) -- A higher-than-normal level of the protein albumin ... clots in the deep veins of the lungs and ... (VTEs) include deep vein thrombosis (DVT), a clotting in ...
... NIH and Robert Wood Johnson Foundation-Sponsored Study Focuses on ... 5 Nearly 75 percent of children ages 3-6 ... getting enough exercise. A focus group study of child ... several reasons children are not getting as much physical ...
Cached Medicine News:Health News:Ohio Selects APS Healthcare to Manage Unified Population Health Management Program for State Employees 2Health News:NABP Position Paper Calls for Action Against Proliferation of Rogue Internet Drug Outlets 2Health News:NABP Position Paper Calls for Action Against Proliferation of Rogue Internet Drug Outlets 3Health News:Medco to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference 2Health News:Writing Disorder May Be Common Among Kids 2Health News:Urine Test Predicts Vein Clot Risk 2Health News:Urine Test Predicts Vein Clot Risk 3Health News:ABCs and No Skinned Knees: Study Reveals Various Barriers to Physical Activity in Child Care 2Health News:ABCs and No Skinned Knees: Study Reveals Various Barriers to Physical Activity in Child Care 3
Preclude Dura Substitute is the only non-biological membrane designed to "seal" around suture holes. 0.3 mm as nominal thickness....
... synthetic absorbable implant for the bridging of Dura ... is pliable, regardless of being used dry or ... must be taken, while implanting, to ensure that ... is oriented towards the cortex or the spinal ...
... is a non-absorbable dura ... purified polyesterurethane. Its microporous ... of fibroblast, supporting tissue ... minimizes suture channels, resulting ...
The Bovie IDS Series are the latest electrosurgical generators with fully digital implementation....
Medicine Products: